Transaction DateRecipientSharesTypePriceValue
2nd September 2020James R Tobin5,600Open or private sale$56.85$318,360.00
2nd September 2020James R Tobin5,600Exercise of derivative$26.27$147,112.00
25th August 2020James R Tobin17,400Exercise of derivative$26.27$457,098.00
25th August 2020James R Tobin17,400Open or private sale$54.40$946,560.00
3rd August 2020Ronald Asbury Andrews40,000Open or private purchase$1.35$53,880.00
24th June 2020Andrew Scott Walton4,081Grant/award etc.$0.00
24th June 2020Ronald Asbury Andrews4,081Grant/award etc.$0.00
24th June 2020Herm Rosenman4,081Grant/award etc.$0.00
24th June 2020James R Tobin4,081Grant/award etc.$0.00
24th June 2020Richard A Sandberg4,081Grant/award etc.$0.00
Oxford Immunotec Global Plc
Oxford Immunotec Global Plc logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Oxford Immunotec Global Plc develops and commercializes proprietary tests for immunology and infectious disease. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, UK.

Ticker: OXFD
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1586049
Employees: 243
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $165 M (-8%)
Inventory, Net: $13 M (0%)
Assets, Current: $187 M (-13%)
Property, Plant and Equipment, Net: $9 M (20%)
Assets: $207 M (-12%)
Accounts Payable, Current: $2 M (-31%)
Accrued Liabilities, Current: $8 M (0%)
Liabilities, Current: $11 M (-21%)
Other Liabilities, Noncurrent: $32 Th (0%)
Liabilities: $18 M (-17%)
Common Stock, Value, Issued: $272 Th (-1%)
Common Stock, Shares, Issued: $26 M (-1%)
Retained Earnings (Accumulated Deficit): $101 M (20%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $10 M (37%)
Stockholders' Equity (Parent): $189 M (0%)
Liabilities and Equity: $207 M (-12%)
Cost of Revenue: $2 M (-62%)
Gross Margin: $4 M (-73%)
Research and Development: $2 M (-51%)
Sales and Marketing: $5 M (-56%)
General and Administrative Expenses: $6 M (-55%)
Operating Income/Loss: $10 M (-40%)
Provision for income taxes: $136 Th (0%)
EPS (basic): $0.37 (-38%)
EPS (diluted): $0.37 (-38%)